The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

Appendectomy may be a useful addition to medical therapy for preventing relapse of ulcerative colitis among patients in ...

Adding narrowband ultraviolet B (UVB) phototherapy to oral treatment with ritlecitinib (Litfulo) enhanced repigmentation in ...

Abu Dhabi, United Arab Emirates – A groundbreaking ‘Declaration on Longevity and Precision Medicine’ was launched at Abu ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

In 2024, five people and 27 animals in Minnesota contracted the rare bacterial disease tularemia in the seven-county ...